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The highly specialised national service for rare non-lysosomal skeletal muscle glycogen 
storage diseases(GSDs) is the only service world-wide offering multi-disciplinary(MD) care 
for affected patients. The team includes: physician, physiotherapist, clinical nurse specialist, 
clinical psychologist, dietician, sports and exercise physiologist, patient advocate and 
research fellow. Provided services include muscle enzyme analysis, genetic studies, a clinical 
diagnostic and management service. In addition to an MD clinic, telephone clinics, 
information days for newly diagnosed patients and face-to-face therapy reviews are also 
offered. Prospective data (audit of outcome measures used for the NHS commissioning for 
Quality and innovation–CQUIN) from 236 patients will be presented. The majority of patient 
had McArdle disease(n=164). Other diagnoses include: GSDVII(n=6), GSDIX(n=2), 
GSDXIII(n=2) and GSDXV(n=1). The incidence of episodes of severe rhabdomyolysis 
requiring hospital visits was 17% in new referrals and 2.8% in follow-up patients. There was 
a high frequency of overweight/obesity (52%females, 78%males). Patients who completed 
the 12 minute walk test(12MWT) and were divided into 4 groups (< 500m(n=12); 500-
800m(n=31); 800-1000m(n=24) and >1000m(n=8)). A Patient Liaison Panel oversaw the 
production of a reference booklet for GPs and assisted with recruitment to the EUROMAC 
Registry and the Sodium Valproate clinical trial. 
This highly specialised MD national service demonstrates reduced frequency of 
rhabdomyolysis and other complications related to rare GSDs following clinical assessment. 
Patients could be divided into 4 clear cohorts on the basis of severity as assessed by the 
12MWT which showed a positive correlation with quality of life. Improvements in walking 
distance and quality of life were seen in subsequent visits to the clinic, demonstrating 
functional improvement over time. Data from anthropometric assessments highlights the need 
for ongoing dietetic support. 
 
